Improvements in Objective and Subjective Measures of Chronic Cough with Gefapixant: A Pooled Phase 3 Efficacy Analysis of Predefined Subgroups

INTRODUCTION: In phase 3 trials (COUGH-1/COUGH-2), gefapixant 45 mg twice daily significantly reduced 24-h cough frequency vs placebo in refractory or unexplained chronic cough (RCC or UCC). METHODS: Here, the efficacy of gefapixant 45 mg vs placebo was evaluated across COUGH-1/COUGH-2 in predefined...

Descripción completa

Detalles Bibliográficos
Autores principales: Smith, Jaclyn A., Birring, Surinder S., Dicpinigaitis, Peter V., McGarvey, Lorcan P., Morice, Alyn H., Pavord, Ian D., Satia, Imran, Green, Stuart, Iskold, Beata, La Rosa, Carmen, Li, Qing, Martin Nguyen, Allison, Schelfhout, Jonathan, Muccino, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Cough
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9360137/
https://www.ncbi.nlm.nih.gov/pubmed/35895098
http://dx.doi.org/10.1007/s00408-022-00553-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9360137/
https://www.ncbi.nlm.nih.gov/pubmed/35895098
http://dx.doi.org/10.1007/s00408-022-00553-y

Ejemplares similares